Your shopping cart is currently empty

Synonyms: d-Bicuculline, (+)-Bicuculline

| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | $30 | In Stock | In Stock | |
| 25 mg | $43 | In Stock | In Stock | |
| 50 mg | $63 | In Stock | In Stock | |
| 100 mg | $90 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $50 | In Stock | In Stock |
| Description | Bicuculline is an alkaloid extracted from Corydalis decumbens, acting as a competitive antagonist of the neurotransmitter GABAA receptor (IC50 = 2 μM). Bicuculline also blocks Ca2+-activated potassium (SK) channels and inhibits slow afterhyperpolarization (slow AHP). Bicuculline has anticonvulsant effects and is commonly used to establish mouse seizure models. |
| Targets & IC50 | GABAA receptor:2 μM |
| In vitro | Methods: In hippocampal CA1 pyramidal neurons from WT and PGC-1α−/− mice, Bicuculline (1 μM) was applied via bath-dialysis. Following stable perfusion, the I/E ratio was calculated from whole-cell voltage-clamp recordings. Results: PGC-1α−/− mice exhibited approximately double the amplitude of double-synaptic IPSCs compared to WT mice, with a significantly elevated I/E ratio. Bicuculline restored both IPSCs and the I/E ratio in PGC-1α−/− mice to WT levels without affecting EPSCs. [1] Methods: Bicuculline (100 μM) and GABA (50 μM) were added to neonatal mouse (P5) cerebellar cultured astrocytes. GABA was applied for 30 s at 7-minute intervals, and whole-cell patch-clamp recordings were performed. Results: Bicuculline (100 μM) blocked (90.5 ± 3.7%) the currents induced by 50 μM GABA. [2] |
| In vivo | Methods: Male SD rats received subcutaneous injections of Bicuculline (1, 4 mg/kg). Blood and brain tissue samples were collected at 10, 30, and 110 min post-administration. Plasma and brain tissue drug concentrations were measured by LC-MS/MS. Seizure grades were observed and recorded. Results: Bicuculline exhibited dose-dependent brain penetration. Tmax in brain tissue was 10 min in the 1 mg/kg group and 30 min in the 4 mg/kg group. Seizures (≥ Grade III) were induced at brain concentrations >880 ng/g.[2] |
| Synonyms | d-Bicuculline, (+)-Bicuculline |
| Molecular Weight | 367.35 |
| Formula | C20H17NO6 |
| Cas No. | 485-49-4 |
| Smiles | [H][C@]1(OC(=O)c2c3OCOc3ccc12)[C@@]1([H])N(C)CCc2cc3OCOc3cc12 |
| Relative Density. | 1.3694 g/cm3 (Estimated) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 16.67 mg/mL (45.38 mM), Sonication is recommended. Ethanol: < 1 mg/mL (insoluble or slightly soluble) | |||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.44 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 µL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.